Specimen Collection Manual and Test Catalog
HEPATITIS B SURFACE ANTIGEN WITH REFLEX TO PCR
Geisinger Epic Procedure Code: LAB4792 Geisinger Epic ID: 183960Test Restriction: ORDER LIMITED TO NEPHROLOGY
Serum AND plasma.
Collect two tubes
1 mL aliquot, minimum 0.5 mL SST tube and collect one 6 mL pink top EDTA or three 3mL lavender top EDTA tubes
This test is restricted and only orderable by Nephrology/Dialysis.
Send unspun collection tube to testing lab. Allow serum to clot. Centrifuge to separate serum within 2 hours of collection. Plasma will be separated at testing lab. Separate plasma within one day of collection and transfer plasma to a screw-capped, plastic aliquot tube. Freeze immediately at -20°C.
Refrigerated (2-8°C)
Serum: Stable 14 days at 2-8°, 6 months frozen.
Whole Blood: Refrigerated (2-8°C). Room temperature (15-30°C) up to 24 hours.
Plasma: Refrigerated (2-8°C) up to 72 hours. Room temperature (15-30°C) up to 20 hours. Frozen (-20°C) up to 60 days. Can be subjected to at most 3 freeze thaw cycles. Thawed samples may be stored at 2-8°C for up to 6 hours prior to testing. Frozen (-70°C) long term. Can be subjected to at most 3 freeze thaw cycles. Thawed samples may be stored at 2-8°C for up to 6 hours prior to testing.
Specimens stored or transported at incorrect temperature, stability limits exceeded, improper collection tube used, insufficient volume, improperly labeled/ identified specimens.
Negative. HBV DNA not detected.
Department of Health is notified for PA residents if positive.
The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only.
Qualitative detection of hepatitis B surface antigen and 1uantitation of hepatitis B viral DNA by PCR.
HBSAG, Hepatitis Associated Antigen Hepatitis B surface antigen Hepatitis B Viral Load, HBVL, Viral Load, Hepatitis B, Hep B, Hep B Viral Load, Quant Viral Load
This test is utilized for the detection and quantitation of hepatitis B virus (HBV) DNA in the plasma of patients with HBV infection (i.e., hepatitis B surface antigen positive), monitoring disease progression in chronic HBV infection, and monitoring response to anti-HBV therapy.
Donna Wolk PhD, D(ABMM)